May 20th 2024
Jose Lutzky, MD, discussed the promise of tumor infiltrating lymphocyte therapy for difficult-to-treat advanced melanoma.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Pembrolizumab Monotherapy Elicits Responses in Patients With Advanced Rare Cancers
March 20th 2020Treatment with pembrolizumab demonstrated antitumor activity along with tolerable toxicity in patients with 4 different rare and hard-to-treat malignancies, according to results from a phase II study led by The University of Texas MD Anderson Cancer Center researchers and published in the Journal for ImmunoTherapy of Cancer.
Read More
Adjuvant Ipilimumab Dose Improves Survival Benefit for Resected High-Risk Melanoma
March 17th 2020Adjuvant ipilimumab at a dose of 3 mg/kg demonstrated a survival benefit in patients with resected high-risk melanoma compared with high-dose interferon alfa-2b, according to the findings for a phase III E1609 clinical trial from the North American Intergroup.
Read More
Death By Cancer Shows Decline in the 2020 Annual Report to the Nation on the Status of Cancer
March 17th 2020From 2001 to 2017, the cancer death rates continued to decline in the United States, and these decreases were observed in all major racial and ethnic groups, as well as in males, females, adolescents, young adults, and children. However, the rates of cancer incidence for all cancers slightly increased in females from 2012 to 2016, according to the Annual Report to the Nation on the Status of Cancer, which was published in Cancer.<sup> </sup>
Read More
Bevacizumab Biosimilar Under Review by FDA
March 9th 2020The FDA has accepted a Biologics License Application for MYL-1402O, a proposed biosimilar to bevacizumab, according to a press release from co-developers Biocon and Mylan. The BLA is seeking approval for the biosimilar as a treatment for multiple types of cancer and the FDA has set an action date goal of December 27, 2020, for a decision on the BLA.
Read More
A Look Back at FDA News from February 2020
March 4th 2020In February 2020, the FDA gave indications to multiple therapies meant for treatment of solid tumor and hematologic malignancies. FDA action included 10 Priority Reviews, 2 Breakthrough Therapy designations, and 2 Fast Track designations.
Read More
Study Confirms Safety and Effectiveness of Cemiplimab in Squamous Cell Carcinoma
March 2nd 2020Cemiplimab is an active treatment option for locally advanced cutaneous squamous cell carcinoma and has an acceptable safety profile, according to the results of an international phase II open-label study published recently in Lancet Oncology.
Read More
Adjuvant T-VEC Is Superior to Surgery Alone in Melanoma
February 26th 2020Adjuvant treatment with talimogene laherparepvec in patients with resectable advanced melanoma demonstrated better recurrence-free survival and overall survival compared with surgery alone, according to results of a study presented at a poster session at the 16th International Congress of the Society for Melanoma Research.
Read More
Liquid Biopsy May Predict Relapse Risk and Aid Therapy Decision-Making in Node-Positive Melanoma
February 6th 2020Performing a liquid biopsy of circulating tumor cells may help identify patients who are at risk for node-positive melanoma relapse and identify patients who wish to avoid the toxicities associated with systemic adjuvant therapy, according to the results of a prospective study from The University of Texas MD Anderson Cancer Center, which was recently published in Clinical Cancer Research.
Read More
Lenvatinib/Pembrolizumab Shows Promising Antitumor Activity and Safety in Select Solid Tumors
January 30th 2020In a phase II trial, the combination of lenvantinib and pembrolizumab demonstrated a manageable safety profile and encouraging antitumor activity in patients with selected advanced solid tumors. The decision to combine the agents was based on preclinical data, which suggested that VEGF and FGF signaling may enhance the therapeutic efficacy of lenvatinib.
Read More
Triplet Regimen Induces Clinical Benefit at 24-Month Follow-Up in BRAF-Mutant Melanoma
January 21st 2020In an interview with Targeted Oncology, Pier Francesco Ferrucci, MD, discussed the findings from the updated analysis, which he shared in a presentation at the 16th International Congress of the Society for Melanoma Research, highlightening the important takeaways from this follow-up analysis.
Read More
Integrating a geriatric assessment into the care of older adults who are receiving cancer treatment in communi­ty oncology practices improves patient and caregiver satisfaction and encourages commu­nication about aging-related concerns, accord­ing to results of a clinical trial that enrolled 541 patients with advanced cancer.
Read More
Telehealth Delivers Access to Care and Cutting-Edge Clinical Research to Rural Areas
January 11th 2020The present and future benefits of telehealth in oncology can be observed through Tahoe For­est Cancer Center and its affiliation with the UC Davis Cancer Center, use of other remote clinics, and participation in virtual tumor boards. Even though there are roadblocks to telehealth reaching more locations and more patients, the potential benefit warrants the time needed to get over those hurdles.
Read More
Exploring Treatment Options for Patients With Advanced Melanoma
January 9th 2020Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses the current treatment options that are approved around the world for patients with advanced melanoma. These treatments include both immunotherapies, such as immune checkpoint inhibitors, and targeted therapies.
Watch
Experts Reflect on the Most Impactful FDA Moves of 2019
January 4th 2020The FDA granted approval to countless treatments across cancer types throughout 2019 until the end of the year, with a final approval on December 31<sup>st </sup>for the first BRCA targeted therapy in pancreatic cancer. Following the excitement for a new year of further advances, Targeted Oncology followers on Twitter shared their thoughts on some of the most impactful FDA approvals in 2019.
Read More
Immunotherapy Advances Are Explored in Merkel Cell Carcinoma
December 28th 2019Early-stage skin cancers that remain localized are often successfully treated through a variety of surgical techniques as well as radiation therapy, photodynamic therapy, and topical chemotherapy, but advanced cases that are beyond surgery may respond to immunotherapies. This setting will be discussed during the Society for Immunotherapy of Cancer’s 34th Annual Meeting.
Read More
FDA Advisory Committee Supports Tazemetostat for Treatment of Epithelioid Sarcoma
December 19th 2019In a unanimous vote, the Oncologic Drugs Advisory Committee of the FDA is in favor of the benefit-risk profile of tazemetostat for the treatment of patients with metastatic or locally advanced epithelioid sarcoma who are not eligible for curative intent surgery, according to a press release from Epizyme, Inc., manufacturer of the drug.
Read More
ACCC Develops Education Project to Assist Community Centers With Treatment of cSCC
December 17th 2019The Association of Community Cancer Centers has partnered with the AIM at Melanoma Foundation to develop resources through its Multidisciplinary Cutaneous Squamous Cell Carcinoma Care education project to help provide physicians with more information to guide them in the diagnosis and treatment of patients with this type of nonmelanoma skin cancer, according to a press release from ACCC.
Read More
IMspire150 Study Meets Primary Endpoint of PFS in Patients With Melanoma
December 13th 2019The combination of atezolizumab, cobimetinib, and vemurafenib reduced the risk of disease progression or death compared with placebo in patients with BRAF V600 mutation-positive advanced melanoma, meeting the primary endpoint of progression-free survival in the phase III IMspire150 study, according to a press release from Roche.
Read More
FDA Grants Regenerative Medicine Advanced Therapy Designation to ADP-A2M4 for Synovial Sarcoma
December 4th 2019The FDA has granted a Regenerative Medicine Advanced Therapy designation to ADP-A2M4 for the treatment of patients with synovial sarcoma, according to a press release from Adaptimmune Therapeutics, developers of the agent.
Read More
2020 Meeting on Cutaneous Malignancies Will Address Next Steps For Immunotherapy
December 3rd 2019Treatment with immunotherapy has become ingrained in the standard of care for treating patients with melanoma, but investigators continue to research new combinations and treatment strategies that can improve patients outcomes. One approach that has generated a great deal of interest and is a significant focus of ongoing trials involves adjuvant and neoadjuvant therapy, according to Jeffrey S. Weber, MD, PhD.
Read More
Tipifarnib Yields 100% Disease Control in HRAS-Mutant Head and Neck Squamous Cell Carcinoma
December 3rd 2019The signal transduction inhibitor tipifarnib induced disease control in all patients with HRAS-mutant head and neck squamous cell carcinoma and a high variant allele frequency, according to preliminary results of a phase II trial presented at the 2019 American Association for Cancer Research–National Cancer Institute–European Organization for Research and Treatment of Cancer International Conference on Molecular Targets and Cancer Therapeutics.
Read More
Immunotherapy Versus Targeted Therapy for Advanced Melanoma
December 3rd 2019Adil Daud, MD, compares the roles of immunotherapy versus dabrafenib plus trametinib targeted therapy combinations in patients with advanced melanoma. The latter combination is appropriate and even preventative in select patients, but the decision between checkpoint immune therapy and immunotherapy comes down to what is best for each patient.
Watch
MRTX849 Shows Safety, Tolerability in Treating KRAS G12C
November 29th 2019In patients whose solid<strong> </strong>tumors harbor a mutation in <em>KRAS </em>G12C, therapy with MRTX849 has produced promising responses and acceptable toxicity across 3 tumors types, according to data presented at the 2019 American Association for Cancer Research–National Cancer Institute–European Organization for Research and Treatment of Cancer International Conference on Molecular Targets and Cancer Therapeutics.
Read More
Experts Explain the Staging and Treatment of cSCC
November 28th 2019In a Targeted Oncology live case-based peer perspectives discussion, Mark Agulnik, MD, and Simon S. Yoo, MD, discussed with a group of physicians the staging criteria and the options for treatment for patients with cutaneous squamous cell carcinoma.
Read More